Advanced Synthesis & Catalysis
10.1002/adsc.201700917
conditions (Scheme 4). The desired product was
obtained in 85% yield with unchanged er value (93:7).
V. Varun, J. Dhineshkumar, K. R. Bettadapur, Y.
Siddaraju, K. Alagiri, K. R. Prabhu, Tetrahedron Lett.
2
017, 58, 803.
[
2] For selected reviews on organocatalysis see: a) D.
Enders, C. Grondal, M. R. M. Hüttl, Angew. Chem. Int.
Ed. 2007, 46, 1570; b) D. W. C. MacMillan, Nature
2
008, 455, 304; c) A. Dondoni, A. Massi, Angew.
Chem. Int. Ed. 2008, 47, 4638; d) S. Bertelsen, K. A.
Jørgensen, Chem. Soc. Rev. 2009, 38, 2178; e) Ł.
Albrecht, H. Jiang, K. A. Jørgensen, Angew. Chem. Int.
Ed. 2011, 50, 8492; f) C. M. R. Volla, L. Atodiresei, M.
Rueping, Chem. Rev. 2014, 114, 2390; g) F. Vetica, R.
M. de Figueiredo, M. Orsini, D. Tofani, T. Gasperi,
Synthesis 2015, 47, 2139; h) F. Vetica, P. Chauhan, S.
Dochain, D. Enders, Chem. Soc. Rev. 2017, 1661.
3] Y.-L. Zhao, Y. Wang, Y.-C. Luo, X.-Z. Fu, P.-F. Xu,
Tetrahedron Lett. 2015, 56, 3703.
Scheme 4. Scale-up synthesis of product 3c.
[
[
In summary, we have developed an efficient
methodology to achieve densely functionalised
pyrazoles bearing a quaternary stereocenter. The
desired potentially bioactive compounds 3 were
obtained with high yield and good enantioselectivities
4] a) T. Nambara, M. Kato, Chem. Pharm. Bull. 1965, 13,
1
435; b) M. Kato, M. Ohnishi, T. Nambara, Chem.
Pharm. Bull. 1968, 16, 2398.
[
5] For selected reviews on desymmetrization reactions
and examples on desymmetrising synthesis of
cyclopentanes see : a) Yeung, R.-J. Chein, E. J. Corey,
J. Am. Chem. Soc. 2007, 129, 10346; b) K. Aikawa, T.
Okamoto, K. Mikami, J. Am. Chem. Soc. 2012, 134,
(
up to 95% yield, up to 91.5:8.5 er). Moreover, a
series of preliminary control experiments have been
accomplished with the aim to clarify the reaction
mechanism. This facile desymmetrizing cross-
dehydrogenative coupling relies on an initial Michael
addition followed by a combination of aromaticity
and extensive conjugation driving to an oxidant- and
metal-free hydride elimination. This interesting new
reactivity could pave the way to new organocatalytic
CDC-based reactions and methodologies.
1
5
2
0329; c) M. S. Manna, S. Mukherjee, Chem. Sci. 2014,
, 1627; d) T. Das, P. Saha, V. K. Singh, Org. Lett.
015, 17, 5088; e) A. Borissov, T. Q. Davies, S. R.
Ellis, T. A. Fleming, M. S. W. Richardson, D. J. Dixon,
Chem. Soc. Rev. 2016; f) X. P. Zeng, Z. Y. Cao, Y. H.
Wang, F. Zhou, J. Zhou, Chem. Rev. 2016, 116, 7330;
g) Y. Zhi, K. Zhao, A. Wang, U. Englert, G. Raabe, D.
Enders, Adv. Synth. Catal. 2017, 359, 1867.
Experimental Section
[
[
6] M. S. Manna, S. Mukherjee, J. Am. Chem. Soc. 2015,
1
37, 130.
To a solution of cyclopentenedione 2 (0.2 mmol, 1 equiv.)
and catalyst A (0.01 mmol, 0.05 equiv.) in MTBE (1 mL,
7] For selected examples on bioactive pyrazoles and
pyrazolones see: a) M. P. Clark, S. K. Laughlin, M. J.
Laufersweiler, R. G. Bookland, T. A. Brugel, A.
Golebiowski, M. P. Sabat, J. A. Townes, J. C. VanRens,
J. F. Djung, M. G. Natchus, B. De, L. C. Hsieh, S. C.
Xu, R. L. Walter, M. J. Mekel, S. A. Heitmeyer, K. K.
Brown, K. Juergens, Y. O. Taiwo, M. J. Janusz, J. Med.
Chem. 2004, 47, 2724; b) V. Hadi, Y.-H. Koh, T. W.
Sanchez, D. Barrios, N. Neamati, K. W. Jung, Bioorg.
Med. Chem. Lett. 2010, 20, 6854; c) S. R. Mandha, S.
Siliveri, M. Alla, V. R. Bommena, M. R. Bommineni, S.
Balasubramanian, Bioorg. Med. Chem. Lett. 2012, 22,
0
.2 M) were added 4Å MS (50 mg) and the pyrazolone 1
(
0.2 mmol, 1 equiv.). The mixture was stirred at room
temperature until complete conversion of the substrates
were achieved by TLC monitoring. The product 3 was
isolated after flash chromatography on silica gel
(
pentane/EtOAc).
Acknowledgements
We thank the BASF SE for the donation of chemicals and
Cornelia Vermeeren for SFC measurements.
5
272; d) V. Kumar, K. Kaur, G. K. Gupta, A. K.
References
Sharma, Eur. J. Med. Chem. 2013, 69, 735.
[
8] For selected reviews on the reactivity of pyrazoles and
pyrazolones see: a) G. Varvounis, in Adv. Heterocycl.
Chem., Vol. 98 (Ed.: R. K. Alan), Academic Press,
2009, pp. 143; b) S. Fustero, M. Sánchez-Roselló, P.
Barrio, A. Simón-Fuentes, Chem. Rev. 2011, 111,
6984; c) A. Schmidt, A. Dreger, Curr. Org. Chem.
2011, 15, 1423; d) P. Chauhan, S. Mahajan, D. Enders,
Chem. Commun. 2015, 51, 12890.
[
1] For selected reviews on C-H activation see: a) V.
Ritleng, C. Sirlin, M. Pfeffer, Chem. Rev. 2002, 102,
1
731; b) J. C. Lewis, R. G. Bergman, J. A. Ellman, Acc.
Chem. Res. 2008, 41, 1013; c) D. A. Colby, R. G.
Bergman, J. A. Ellman, Chem. Rev. 2010, 110, 624; d)
S. H. Cho, J. Y. Kim, J. Kwak, S. Chang, Chem. Soc.
Rev. 2011, 40, 5068; e) G. Song, F. Wang, X. Li, Chem.
Soc. Rev. 2012, 41, 3651; f) S. A. Girard, T. Knauber,
[9] For further details see Supporting Information.
C.-J. Li, Angew. Chem., Int. Ed. 2014, 53, 74; g) E. J. E. [10] Y. He, X. Bao, J. Qu, B. Wang, Tetrahedron: Asymm.
Caro-Diaz, M. Urbano, D. J. Buzard, R. M. Jones,
Bioorg. Med. Chem. Lett. 2016, 26, 5378; h) H. Yang,
X. Yang, W. Tang, Tetrahedron 2016, 72, 6143; i) B.
2015, 26, 1382.
[11] a) H. Nakagawa, R. Ohyama, A. Kimata, T. Suzuki, N.
Miyata, Bioorg. Med. Chem. Lett. 2006, 16, 5939; b) J.
5
This article is protected by copyright. All rights reserved.